Tuberculosis Breakthrough – New Technology To Greatly Reduce Deadly Disease Risk In Hospitals
AsepticSure, a Highly Promising New Disinfection Technology May Hold the Key to Reducing or Even Eliminating TB from Hospitals and Tuberculosis Laboratories, Worldwide.
San Francisco, California, June 12, 2012. Medizone International, Inc. (The Company) (MZEI:OB) (MZEI:QB) announced today that in achieving 100% kill rates with TB in three successive trials, it had achieved another important milestone in its understanding of the antimicrobial limits of its recently launched hospital disinfection technology, AsepticSure™.
Dr. Michael E Shannon, President of Medizone International, stated, "With one third of the world's population currently infected with tuberculosis and a new Extreme Drug Resistant Strain of tuberculosis now sweeping across Asia, central Europe and parts of Africa, we felt compelled to evaluate the efficacy of AsepticSure against this daunting bacteria. With a small increase in treatment time (beyond our standard 90 minute protocol, start to finish) we demonstrated that AsepticSure consistently produces >6 log reductions of Mycobacterium terrae, a well established surrogate organism for Mycobacterium tuberculosis."
Chief Medical Officer for Medizone, Dr. Dick Zoutman added, “Although tuberculosis is not spread through contact with contaminated surfaces; contaminated ventilation systems, isolation wards and tuberculosis laboratories have proven very difficult to disinfect and hence, pose a serious threat to the health and safety of those persons occupying these spaces. Our results indicate that AsepticSure technology can very effectively mitigate that risk."
These findings expand upon Medizone's ground-breaking research already published in the field of HAI control, with implications not just of academic or scientific interest but of significant public health importance as well. There are over 200,000 clinical laboratories in the US and until now, there has been no cost effective way to address their contamination problems. The evidence is now very compelling that AsepticSure offers an extremely effective and surprisingly inexpensive solution, not only for laboratory contamination problems, but environmental contamination problems worldwide.
Dr Shannon closed by saying, “Hospitals and long-term care facilities will have the comfort of knowing that in addition to being able to deal with all of the pathogens commonly associated with HAI, rooms previously occupied by TB patients can now be effectively cleansed to an international sterilization standard of > 6 log for TB. It’s noteworthy that in some cases of significant TB infection, current practice requires the closing of entire wards. AsepticSure will greatly mitigate that need.
“It’s an inescapable fact that the world is facing one of its toughest medical challenges to-date with the massive resurgence of what is tantamount to a contagion-like strain of TB. It will take an extraordinary solution to combat it. In AsepticSure, the world may very well have that solution.”
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com